ALK and lung adenocarcinoma: Kang et al. analyzed data from 8566 patients with advanced lung adenocarcinoma and concluded that upfront NGS testing did not demonstrably improve survival outcomes of oncologic treatment compared to SGT for ALK and EGFR testing [13].